当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.

Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.

Abstract：

OBJECTIVE:This study investigated the expression of cellular apoptosis susceptibility protein (CAS) in serous ovarian carcinoma by immunohistochemistry and compared it with topoisomerase IIalpha (topo IIalpha), bcl-2, bcl-x, the frequency of apoptotic bodies (ABI), mitotic activity, and c-erbB-2 with regard to clinicopathologic variables. METHODS:Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas, 10 serous neoplasms of low malignant potential (LMP), and 41 serous ovarian carcinomas were immunostained with antibodies to CAS, bcl-x, topo IIalpha, bcl-2, and c-erbB-2. Immunostaining for CAS, bcl-x, and bcl-2 was scored concerning approximate percentage of positive tumor cells and relative staining intensity. For c-erbB-2, at least 10% of tumor cells had to display membrane staining. Topo IIalpha-labeling indices were quantitated as the percentage of positively stained nuclei in 1000 tumor cells. ABIs were reported as the number of apoptotic bodies in 1000 tumor cells, mitotic activity as mitotic figures per 10 high power fields. RESULTS:CAS expression was negative in serous cystadenomas and LMP. In contrast, moderate or strong immunostaining was observed in 34 of 41 cases (83%) of serous carcinomas. CAS immunoreactivity was positively related with ABI (P = 0.0170), mitotic activity (P < 0.0001), c-erbB-2 (P = 0.0153), grade (P = 0.0107), and adverse outcome (P = 0.0035), but not with FIGO stage, topo IIalpha, bcl-2, and bcl-x. Other variables indicating outcome were topo IIalpha, c-erbB-2, and ABI. CONCLUSIONS:CAS is frequently upregulated in serous ovarian carcinomas, correlated with apoptosis and mitotic activity, and relevant prognostically. CAS protein expression may serve as a marker of aggressive tumor behavior in serous ovarian carcinomas.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Brustmann H

doi

10.1016/j.ygyno.2003.10.029

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

268-76

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090825803007285

journal_volume

92

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

    abstract：OBJECTIVE:The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus. METHODS:Women with a history of advanced or recurrent gynecologic mal...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.02.022

    authors： Temkin SM,Yamada SD,Fleming GF

    更新日期：2010-06-01 00:00:00

  • TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

    abstract：OBJECTIVE:To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous epithelial ovarian carcino...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.04.039

    authors： Seagle BL,Yang CP,Eng KH,Dandapani M,Odunsi-Akanji O,Goldberg GL,Odunsi K,Horwitz SB,Shahabi S

    更新日期：2015-07-01 00:00:00

  • Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.

    abstract：INTRODUCTION:Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease. Reasons for this disparity in outcome are not well understood. METHODS:The Surveillance, Epidemiology, and End-Results Program data were used to sample ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.11.041

    authors： Trimble EL,Harlan LC,Clegg LX,Stevens JL

    更新日期：2005-03-01 00:00:00

  • Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.

    abstract：OBJECTIVE:The establishment of clinical features identifying patients at a heightened risk for the development of carboplatin hypersensitivity may assist in the management of this important toxicity. Based on a previous report suggesting a history of "bee sting" allergy predicted for paclitaxel hypersensitivity, we att...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/s0090-8258(03)00155-0

    authors： Markman M,Zanotti K,Kulp B,Peterson G,Markman M

    更新日期：2003-06-01 00:00:00

  • Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

    abstract：BACKGROUND:Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown. METHODS:"Window of opportunity" study of metformin in women with operable endometrial cancer (EC). Eleven newly diagnosed, untreated, non-diabetic patients with EC received metform...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.06.014

    authors： Laskov I,Drudi L,Beauchamp MC,Yasmeen A,Ferenczy A,Pollak M,Gotlieb WH

    更新日期：2014-09-01 00:00:00

  • Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.

    abstract：OBJECTIVE:Using data from a case-control study of endometrial cancer, we investigated the relationship between the progestin and estrogen potency in combination oral contraceptives (OCs) and the risk of developing endometrial cancer. METHODS:Subjects included 434 endometrial cancer cases and 2,557 controls identified ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2006.03.046

    authors： Maxwell GL,Schildkraut JM,Calingaert B,Risinger JI,Dainty L,Marchbanks PA,Berchuck A,Barrett JC,Rodriguez GC

    更新日期：2006-11-01 00:00:00

  • Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report.

    abstract：INTRODUCTION:We describe a case of conservatively treated endometrial endometrioid (EE) adenocarcinoma which showed an aggressive clinical outcome after pregnancy. CASE:A 30-year-old woman with a well differentiated EE adenocarcinoma decided to attempt a conservative approach and underwent progestin treatment with sub...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.05.025

    authors： Ferrandina G,Zannoni GF,Gallotta V,Foti E,Mancuso S,Scambia G

    更新日期：2005-10-01 00:00:00

  • Long-term sexual function in survivors of vulvar cancer: a cross-sectional study.

    abstract：OBJECTIVES:To assess sexual function of vulvar cancer survivors who received extensive and less extensive treatment. To explore associations between sexual function and patient, disease, treatment, and psychological variables. METHODS:Sexual function (Female Sexual Function Index, FSFI), mental and physical well-being...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2012.04.015

    authors： Hazewinkel MH,Laan ET,Sprangers MA,Fons G,Burger MP,Roovers JP

    更新日期：2012-07-01 00:00:00

  • The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter?

    abstract：BACKGROUND:Survivorship and quality of life issues are becoming increasingly relevant in endometrial cancer as a result of the marked increase in incidence of the disease combined with excellent and improving long term survival. OBJECTIVE:The purpose of this study was to evaluate the effect of obesity on quality of li...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.11.018

    authors： Smits A,Lopes A,Das N,Bekkers R,Galaal K

    更新日期：2014-01-01 00:00:00

  • Accuracy of diffusion-weighted echo-planar MR imaging and ADC mapping in the evaluation of residual cervical carcinoma after radiation therapy.

    abstract：OBJECTIVES:The impact of diffusion-weighted imaging (DWI) and apparent diffusion coefficients (ADCs) of MR imaging on the evaluation of residual Uterine Cervical Carcinoma after Radiation Therapy, in addition to conventional MR images. METHODS:Fourty-nine women presenting with a uterine cervical cancer were examined w...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.06.009

    authors： Levy A,Caramella C,Chargari C,Medjhoul A,Rey A,Zareski E,Boulet B,Bidault F,Dromain C,Balleyguier C

    更新日期：2011-10-01 00:00:00

  • Adjunctive hysterectomy following radiation therapy for bulky carcinoma of the uterine cervix: prognostic implications of tumor persistence.

    abstract：:Twenty-five patients underwent adjunctive extrafascial hysterectomy 14-60 days following completion of external and intracavitary irradiation for bulky carcinoma of the uterine cervix. Review of the operative histopathology and correlation with subsequent patient outcomes suggests that morphologically persistent cance...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(87)90217-4

    authors： Russell AH,Burt AR,Ek M,Russell KJ,Cain JM,Greer BE,Tamimi HK,Figge DC

    更新日期：1987-10-01 00:00:00

  • Novel technique for the complete staging of endometrial cancer by single-port laparoscopy.

    abstract：OBJECTIVE:Our aim was to evaluate the feasibility of a novel technique using single-port laparoscopy for the complete surgical staging of endometrial cancer. METHODS:Total hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy and para-aortic lymphadenectomy was performed using a single-port device in t...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.12.014

    authors： Zapardiel I,Moreno E,Piñera A,De Santiago J

    更新日期：2016-02-01 00:00:00

  • Benign müllerian inclusions in pelvic and paraaortic lymph nodes.

    abstract：OBJECTIVE:This study was undertaken to determine the incidence and distribution of the location of benign müllerian inclusions in pelvic and paraaortic lymph nodes. METHODS:A total of 114 patients operated on for gynecologic malignancy between 1995 and 1998 underwent surgery including systematic pelvic (n = 114) or pe...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5867

    authors： Reich O,Tamussino K,Haas J,Winter R

    更新日期：2000-08-01 00:00:00

  • An international assessment of ovarian cancer incidence and mortality.

    abstract：OBJECTIVE:To assess and characterize the temporal variation in ovarian cancer incidence and mortality by age within countries in the Americas, Europe, Asia, and Oceania. METHODS/MATERIALS:Data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program in the United States (U.S.) were used...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.03.026

    authors： Lowe KA,Chia VM,Taylor A,O'Malley C,Kelsh M,Mohamed M,Mowat FS,Goff B

    更新日期：2013-07-01 00:00:00

  • HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

    abstract：OBJECTIVE:Vaccination of young women (15-25 years of age) against human papillomavirus (HPV) has been shown to be very efficacious in preventing the development of moderate or severe cervical precancerous lesions associated with HPV-16 or -18. As the highest rates of new infections with high-risk (i.e., oncogenic) HPV ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.09.021

    authors： Castellsagué X,Schneider A,Kaufmann AM,Bosch FX

    更新日期：2009-12-01 00:00:00

  • Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.

    abstract：OBJECTIVES:Epidermal Growth Factor Receptor (EGF-R) up-regulation in cervical cancer cells leads to an increase in cell proliferative Insulin-like Growth Factor II (IGF-II) and Vascular Endothelial Growth Factor (VEGF) and a decrease of the anti-proliferative IGF-binding protein-3 (IGF-BP3). The objectives for this stu...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.12.011

    authors： Mathur RS,Mathur SP

    更新日期：2005-04-01 00:00:00

  • Impact of obesity on surgical and oncologic outcomes in ovarian cancer.

    abstract：OBJECTIVES:The aim of this study is to determine the impact of obesity on surgical and oncologic outcomes after primary debulking surgery (PDS) in advanced epithelial ovarian cancer (EOC). METHODS:Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.07.103

    authors： Kumar A,Bakkum-Gamez JN,Weaver AL,McGree ME,Cliby WA

    更新日期：2014-10-01 00:00:00

  • Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.

    abstract：OBJECTIVES:To evaluate the role of LPA in regulating E-cadherin cell surface expression, adhesion, and invasion in epithelial ovarian carcinoma (EOC) cells. METHODS:E-cadherin mRNA expression in OVCA429 and IOSE-29 cells was evaluated by real-time RT-PCR. Immunofluorescence and Western blot analysis were performed to ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.10.027

    authors： Gil OD,Lee C,Ariztia EV,Wang FQ,Smith PJ,Hope JM,Fishman DA

    更新日期：2008-02-01 00:00:00

  • A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

    abstract：PURPOSE:Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib pr...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2017.03.013

    authors： Jandial DA,Brady WE,Howell SB,Lankes HA,Schilder RJ,Beumer JH,Christner SM,Strychor S,Powell MA,Hagemann AR,Moore KN,Walker JL,DiSilvestro PA,Duska LR,Fracasso PM,Dizon DS

    更新日期：2017-05-01 00:00:00

  • Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.

    abstract：OBJECTIVE:The purpose of this work was to evaluate the ability of testing for high-risk human papillomavirus (HPV) types using the hybrid capture technique to predict the presence of cervical intraepithelial neoplasia (CIN) II,III in patients with repeated atypical squamous cells of undetermined significance (ASCUS) an...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.2000.5929

    authors： Fait G,Kupferminc MJ,Daniel Y,Geva E,Ron IG,Lessing JB,Bar-Am A

    更新日期：2000-11-01 00:00:00

  • Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: A case report.

    abstract：OBJECTIVE:Inguinal metastasis is a rare manifestation of ovarian cancer. Autopsy studies have reported inguinal metastasis in 0-3% of patients with advanced disease. CASE REPORT:We describe a 43-year-old patient with ovarian cancer limited to the adnexa who had an isolated metastasis in an enlarged inguinal lymph node...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1999.5592

    authors： Scholz HS,Lax S,Tamussino KF,Petru E

    更新日期：1999-12-01 00:00:00

  • Advanced ovarian carcinoma diagnosed during pregnancy in a patient with human immunodeficiency virus infection.

    abstract：:Many malignancies appear to occur with increased frequency and aggressive patterns of spread in patients seropositive for human immunodeficiency virus (HIV). The relationship between HIV infection and cervical neoplasia suggests that these patients present with more advanced disease and demonstrate poor response to th...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1993.1224

    authors： Buckley SL,Molpus K,Carr MB,Jones HW 3rd

    更新日期：1993-09-01 00:00:00

  • Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

    abstract：OBJECTIVE:We wished to compare the cost-effectiveness of three chemotherapy regimens for treatment of recurrent platinum-sensitive ovarian cancer. METHODS:A Markov decision tree was constructed comparing three chemotherapy regimens: (1) carboplatin alone (C); (2) paclitaxel/carboplatin (PC); (3) gemcitabine/carboplati...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.06.029

    authors： Havrilesky LJ,Secord AA,Kulasingam S,Myers E

    更新日期：2007-11-01 00:00:00

  • Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

    abstract：OBJECTIVES:Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment. METHODS:Eligible women with advanced uterine leiomyosarcoma were treated with gemcitabine 900 mg/m(2) over 90 min, o...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2008.03.010

    authors： Hensley ML,Blessing JA,Mannel R,Rose PG

    更新日期：2008-06-01 00:00:00

  • Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3.

    abstract：OBJECTIVE:Different Human Papilloma Virus (HPV) tests are currently used. An integrated comparison of the Amplicor, Cobas4800, PreTect HPV-Proofer and APTIMA HPV tests has not been done. METHODS:We compared the high-risk HPV detection power of these HPV tests in 528 consecutive population-based follow-up Liquid-Based ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.07.024

    authors： Ovestad IT,Vennestrøm U,Andersen L,Gudlaugsson E,Munk AC,Malpica A,Feng W,Voorhorst F,Janssen EA,Baak JP

    更新日期：2011-11-01 00:00:00

  • Racial disparities in survival in malignant germ cell tumors of the ovary.

    abstract：OBJECTIVE:To investigate racial disparities with respect to adjuvant treatment and survival in patients presenting with malignant ovarian germ cell tumors (OGCT). METHODS:The National Cancer Database (NCDB) was used to identify women diagnosed with OGCT. Demographic data were abstracted, including stratification by ra...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2016.01.006

    authors： Hinchcliff E,Rauh-Hain JA,Clemmer JT,Diver E,Hall T,Stall J,Growdon W,Clark R,Schorge J

    更新日期：2016-03-01 00:00:00

  • Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

    abstract：OBJECTIVE:This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC). METHODS:Primary endpoints were maximum tolerated dose of sorafenib with weekly topotecan (phase I) and response rate (phase...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2011.08.033

    authors： Ramasubbaiah R,Perkins SM,Schilder J,Whalen C,Johnson CS,Callahan M,Jones T,Sutton G,Matei D

    更新日期：2011-12-01 00:00:00

  • Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system.

    abstract：:To determine the morbidity associated with delivery of intraperitoneal chemotherapy via subcutaneous semipermanent infusion catheters, we analyzed the data on 227 patients treated from April 1985 through December 1989. A total of 249 catheters were inserted and used to administer chemotherapy in these patients. There ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(91)90266-8

    authors： Davidson SA,Rubin SC,Markman M,Jones WB,Hakes TB,Reichman B,Almadrones L,Chapman D,Lewis JL Jr,Hoskins WJ

    更新日期：1991-05-01 00:00:00

  • Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.

    abstract：OBJECTIVE:Our aim was to characterize the pathological, molecular and clinical outcomes of clear cell carcinoma of the endometrium (CCC). METHODS:CCC underwent ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classification identifying four molecular subtypes: i) 'POLEmut' for ECs with pathogenic P...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.04.043

    authors： Kim SR,Cloutier BT,Leung S,Cochrane D,Britton H,Pina A,Storness-Bliss C,Farnell D,Huang L,Shum K,Lum A,Senz J,Lee CH,Gilks CB,Hoang L,McAlpine JN

    更新日期：2020-07-01 00:00:00

  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.

    abstract：OBJECTIVE:ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance. We comprehensively evaluated this gene and flanking regions for an association with clinical outcome in epithelial ovarian cancer (EOC). METHODS:The best candidates from fine-mapping analysis of 2...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.07.107

    authors： Johnatty SE,Beesley J,Gao B,Chen X,Lu Y,Law MH,Henderson MJ,Russell AJ,Hedditch EL,Emmanuel C,Fereday S,Webb PM,Australian Ovarian Cancer Study Group.,Goode EL,Vierkant RA,Fridley BL,Cunningham JM,Fasching PA,Beckmann

    更新日期：2013-10-01 00:00:00